Skip to content

AI Drug Discovery Startup Insilico Sees Possible IPF Treatment Enter Human Trials

Potential treatments for idiopathic pulmonary fibrosis (IPF) developed by AI drug discovery startup Insilico Medicine have entered human trials.

The Hong Kong-based firm entered initial human trials for its IPF drug last November.

IPF is a condition in which the lungs become scarred and breathing becomes increasingly difficult.

Insilico only announced the nomination of the candidate last February and claimed to have developed the candidate on a budget of $2.6 million, less than its rivals.

Now, a group of 80 healthy volunteers will be part of the tests. Groups of 10 will see five single ascending doses and five ascending dose cohorts of the prospective drug ISM001-055. The primary endpoints determine the maximum tolerated dose and establish dosage recommendations for potential Phase II clinical trials in the future.

Insilico’s initial tests took place on just eight volunteers. The startup said results found a microdose of ISM001-055 as “a favorable pharmacokinetics and safety profile.”

“Modern deep learning technologies enable us to perform target identification using longitudinal biological data from healthy subjects and make inferences into a variety of diseases,” said Alex Zhavoronkov, PhD., founder and CEO of Insilico Medicine.

The startup’s AI suite includes PandaOmics, which narrows down disease targets, Chemistry42 for generating potential compounds and InClinico for aiding in the design of clinical trials.

Insilico Medicine closed a $37 million series B round last fall, securing investments from Baidu, Sinovation Ventures and Qiming Venture Partners, among others.

Written by AI Business and republished with permission.



Reach out to us at [email protected]

Related Posts

Procter & Gamble on Scaling AI for Enterprise

Procter & Gamble on Scaling AI for Enterprise

Data, talent, platforms and trust: these are the four key pillars firms need when building AI into their applications according…
Scaling Up: AWS’s Allie Miller Outlines the Key Trends in AI and Machine Learning

Scaling Up: AWS’s Allie Miller Outlines the Key Trends in AI and Machine Learning

We are entering an AI world where start-ups are transforming everyday lives through artificial intelligence and machine learning. AWS’ Allie…

ScaleUp:AI uses cookies to enhance your experience and help us analyze website usage. By continuing to browse or dismissing this banner, you indicate your agreement as outlined in our Privacy Policy.